NCT04922333View on ClinicalTrials.gov

Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Bone Loss
Interventions
DRUG

Risedronate

150mg over-encapsulated risedronate

DRUG

Placebo

Capsules containing placebo tablets

Trial Locations (1)

27157

RECRUITING

Wake Forest School of Medicine, Winston-Salem

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Wake Forest University Health Sciences

OTHER